Gilead Sciences Inc. announced several promotions within the company's senior management team. Robin Washington, Chief Financial Officer (CFO), has been promoted to Executive Vice President; Paul Carter, formerly Senior Vice President, International Commercial Operations, has been promoted to Executive Vice President with responsibility for Gilead's worldwide commercial organization; and John McHutchison, MD, formerly Senior Vice President, Liver Disease Therapeutics, has been promoted to Executive Vice President and will assume additional responsibility for clinical development programs in the areas of oncology, respiratory diseases and inflammation. Ms. Washington joined Gilead in 2008 as Senior Vice President and CFO.

She oversees the company's finance, information technology and investor relations functions, reporting to John Milligan, PhD, Gilead's President and Chief Operating Officer. Mr. Carter joined Gilead Sciences in April 2006 to head its European commercial organization. Later that year he assumed additional responsibility for Gilead's growing operations outside of Europe and North America.

Dr. McHutchison joined Gilead in 2010 as Senior Vice President, Liver Disease Therapeutics. In his newly expanded role, he will be responsible for Gilead's development programs in oncology, respiratory diseases and inflammation. Dr. McHutchison will continue to report to Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer.